Gilead Sciences, Inc. $GILD Stake Boosted by HUB Investment Partners LLC

HUB Investment Partners LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 18.0% during the third quarter, Holdings Channel reports. The firm owned 58,449 shares of the biopharmaceutical company’s stock after buying an additional 8,913 shares during the period. HUB Investment Partners LLC’s holdings in Gilead Sciences were worth $6,488,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Brighton Jones LLC increased its position in Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 2,450 shares during the period. Bison Wealth LLC bought a new stake in Gilead Sciences in the fourth quarter valued at $215,000. Sivia Capital Partners LLC boosted its holdings in shares of Gilead Sciences by 16.8% during the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after acquiring an additional 602 shares during the period. Ethos Financial Group LLC bought a new position in shares of Gilead Sciences during the second quarter worth about $306,000. Finally, Golden State Wealth Management LLC increased its holdings in shares of Gilead Sciences by 43.0% in the 2nd quarter. Golden State Wealth Management LLC now owns 1,234 shares of the biopharmaceutical company’s stock worth $137,000 after acquiring an additional 371 shares during the period. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on GILD shares. UBS Group upped their target price on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Citigroup reissued a “buy” rating on shares of Gilead Sciences in a report on Friday. Royal Bank Of Canada raised their target price on Gilead Sciences from $103.00 to $118.00 and gave the company a “sector perform” rating in a research report on Wednesday, February 11th. TD Cowen lifted their target price on Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Finally, Truist Financial boosted their price target on Gilead Sciences from $145.00 to $152.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Twenty-three equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $156.72.

Insider Transactions at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total transaction of $617,500.00. Following the completion of the transaction, the director owned 8,920 shares of the company’s stock, valued at $1,101,620. This trade represents a 35.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00. Following the transaction, the chief executive officer directly owned 566,698 shares in the company, valued at approximately $76,504,230. The trade was a 16.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 309,280 shares of company stock worth $43,935,470. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Down 0.7%

Gilead Sciences stock opened at $144.08 on Friday. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $157.29. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. The stock has a market capitalization of $178.86 billion, a PE ratio of 21.28, a price-to-earnings-growth ratio of 1.90 and a beta of 0.37. The firm has a 50 day simple moving average of $138.29 and a 200-day simple moving average of $125.75.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date is Friday, March 13th. Gilead Sciences’s payout ratio is currently 46.68%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.